眼科

• 青光眼防治公益专栏 • 上一篇    下一篇

新型抗青光眼药物——固定联合制剂

贺翔鸽   

  1. 400042 重庆,第三军医大学野战外科研究所 大坪医院眼科
  • 收稿日期:2015-10-02 出版日期:2015-11-25 发布日期:2015-12-03
  • 通讯作者: 贺翔鸽,Email: hexiangge2011@126.com E-mail:hexiangge2011@126.com

New anti-glaucoma therapy: fixed combination drugs

HE Xiang-ge   

  1. Department of Ophthalmology, the Da-ping Hospital, the Third Military Medical University, Chongqing 400042, China
  • Received:2015-10-02 Online:2015-11-25 Published:2015-12-03
  • Contact: HE Xiang-ge,Email: hexiangge2011@126.com E-mail:hexiangge2011@126.com

摘要:

近年新型抗青光眼药物——固定联合制剂陆续在我国上市。固定联合制剂是由两种或两种以上不同降眼压机制的青光眼药物联合组成,降压效果强于单制剂或不劣于它们协同使用。固定联合制剂仍然存在与单制剂类似的副作用,但少于单制剂。固定联合制剂为临床上使用两种以上药物降眼压患者提供更有力的降压效果,提高治疗方案的便利性,减少多瓶用药防腐剂对眼表的损害,改善病人的依从性和药物治疗的持久性。

关键词: 青光眼/药物疗法, 固定联合制剂

Abstract:

 In recent years, new type antiglaucoma medication, fixed combination drugs,  were commercially available in our country. The drugs were combination by two or three anti-glaucoma medication individual components with different mechanism of lowering Intraocular pressure. The efficacy of fixed combination drugs was increased than their individual components. There were the same adverse effects as or less their individual components. These simplify the anti-glaucoma therapeutic regimen, reducing exposure to preservative, and improved the tolerability and compliance of patients.

Key words: glaucoma/drug therapy, fixed combination drugs